Arteriosclerosis

45 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Arterial Occlusive Diseases, Cardiovascular Diseases

Narrower: Atherosclerosis 20, Coronary Artery Disease 24, Peripheral Arterial Disease 2

Treatments and conditions

Arteriosclerosis
Treatment and conditionWhere it standsTrials
"Trained Eye" (Angiography-Guided) LM PCI for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
1 Stent for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
2 Stents for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Aroxxen for coronary artery diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Autoinjector + EVOLOCUMAB for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BiOSS LIM C for coronary artery diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Calf Plantar flexion + Dietary nitrate for peripheral arterial diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Canakinumab for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) + Colchicine 0.5 mg for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) + Colchicine-placebo 0.5 mg for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Clazakizumab for atherosclerosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine for coronary artery diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine 0.5 mg for atherosclerosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine 0.5 mg + Usual Care Group for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine-placebo 0.5 mg + Usual Care Group for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Coronary Sinus Reducer for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
EA-230 90mg/kg/hour for coronary artery diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enlicitide Decanoate for arteriosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Essential Pro Paclitaxel Drug-Eluting Balloon for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Evolocumab for coronary artery diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Intensified medical follow-up and glucose-lowering drugs for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Left main stenting with intravascular lithotripsy for atherosclerosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Left main stenting with intravascular lithotripsy for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lepodisiran for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lepodisiran Sodium for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Maridebart Cafraglutide for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Muvalaplin for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
obicetrapib 10 mg + ezetimibe 10 mg FDC daily for coronary artery diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Polycap for atherosclerosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Qidan Xiaoke Granules + Standard Medical Therapy for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Regadenoson for coronary artery diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Retatrutide for coronary artery diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Retatrutide for peripheral arterial diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Selnoflast for atherosclerosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Semaglutide for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tertinat for atherosclerosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tertinat for coronary artery diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ticagrelor for coronary artery diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)7
VERVE-102 for atherosclerosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
VERVE-102 for coronary artery diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Very-short DAPT less than 1 month after PCI for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
YMI024 for coronary artery diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ziltivekimab for atherosclerosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Ziltivekimab for coronary artery diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zotarolimus-eluting stent (Endeavor Resolute) for coronary artery diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.